Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis

Anti-programmed cell death-1 (PD-1) antibodies has been approved to treat HCC. Some PD-1 ligands (PD–L1 and PD–L2) negative tumors respond to treatment of anti-PD-1 antibodies, and this fact may be caused by the expression of PD-1 ligands on non-tumor cells. PD–L1 was recently found to be expressed...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasuoka, Hidetaka, Asai, Akira, Ohama, Hideko, Tsuchimoto, Yusuke, Fukunishi, Shinya, Higuchi, Kazuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316832/
https://www.ncbi.nlm.nih.gov/pubmed/32587357
http://dx.doi.org/10.1038/s41598-020-67497-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316832/
https://www.ncbi.nlm.nih.gov/pubmed/32587357
http://dx.doi.org/10.1038/s41598-020-67497-2

Ejemplares similares